ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Clinical trial NCT04467905 · COMPLETED

Trial details

NCT number: NCT04467905
Sponsor: Milestone Pharmaceuticals Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Atrial Fibrillation

Start date: 2020-11-19
Primary completion: 2023-08-03
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.